Prestige Consumer Healthcare Inc. PBH

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

• Zacks Investment Research 1 oct

  Best Value Stocks to Buy for October 1st

  Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. The market is now focused on the upcoming Friday employment report. Two stocks highlighted as strong buys are BP, an integrated energy company with a Zacks Rank #1 and improving earnings estimates, and Prestige Consumer Healthcare, also with a Zacks Rank #1 rating.

  

• Zacks Investment Research 30 sept

  PBH vs. NEOG: Which Stock Is the Better Value Option?

  A comparison of two Medical-Products stocks reveals that Prestige Consumer Healthcare (PBH) offers superior value compared to Neogen (NEOG). While both companies share a Zacks Rank #2 (Buy) rating with improving earnings outlooks, PBH demonstrates significantly better valuation metrics with a forward P/E of 10.26 versus NEOG's 41.51, a PEG ratio of 1.47 versus 4.15, and a Value grade of A versus D.

  

• Zacks Investment Research 2 sept

  Is This the Right Time to Add PBH Stock to Your Portfolio?

  Prestige Consumer Healthcare (PBH) is a Zacks Rank #2 (Buy) stock benefiting from strategic acquisitions of Breathe Right and LaCorium Health, expected to add nearly 20% to its revenue base and lift fiscal 2027 guidance to $1.29-$1.315 billion. The company's e-commerce channel has grown to 18% of net sales with double-digit growth momentum. However, elevated debt levels ($2.0 billion net debt) and foreign exchange exposure pose risks to profitability.

  

• GlobeNewswire Inc. 6 jul

  Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date

  Prestige Consumer Healthcare completed its acquisition of LaCorium Health for approximately $150 million on July 1, 2026. The company also priced a $400 million offering of 6.25% senior notes due 2034, with proceeds intended to redeem $400 million of existing 5.125% senior notes due January 2028. LaCorium, an Australian therapeutic skincare company generating ~$40 million in annual revenue, is expected to contribute approximately $12 million in EBITDA post-integration.

  

• The Motley Fool 3 jul

  Alphabet Joined the Dow and Became a Top Holding in Berkshire Hathaway's Portfolio. But This Stock Could Be an Even Better Buy.

  While Alphabet's addition to the Dow and prominence in Berkshire Hathaway's portfolio has garnered significant attention, Prestige Consumer Healthcare may offer better investment potential. Prestige completed its largest acquisition, purchasing Breathe Right and other OTC brands for $1.045 billion, expanding its portfolio of category-leading brands. The company is also positioning itself to benefit from GLP-1 weight-loss medication side effects through its existing brands like Dramamine and Fleet. However, the acquisition has elevated debt to 4.0x EBITDA, requiring successful execution to reduce leverage by 2028.